Working with Advocacy Groups Focusing on Neonatal Onset Multisystem Inflammatory Disease (NOMID) скачать в хорошем качестве

Working with Advocacy Groups Focusing on Neonatal Onset Multisystem Inflammatory Disease (NOMID)

Len Walt, Vice President, Head of Medical Affairs, Sobi in North America, talks about working with advocacy groups and physicians in neonatal onset multisystem inflammatory disease (NOMID), a treatment for neonatal onset multisystem inflammatory disease (NOMID). Kineret (anakinra) is a recombinant protein drug that blocks the biological activity of IL-1a and IL -1b by binding to interleukin-1 type 1 receptor (IL-R 1), expressed in a variety of tissues and organs, and thereby blocking the interleukin-1 (IL-1) signalling. IL-1 is a key mediator of inflammation and a significant contributor to autoinflammatory diseases. Kineret has a well-characterised safety profile, a quick onset of action and a short half-life.